Impact of Insurance Coverage on the Use and Effects of Smoking Cessation Medications
AbstractTobacco use is not only the chief preventable cause of death, but it is also a very important contributor to the cause or complications of most chronic diseases. Therefore, facilitating smoking cessation should be very important to more effective disease management. Well-accepted, evidence-based guidelines describe effective clinical actions in support of smoking cessation; however, they are not followed as well as desired. This article focuses on the question of whether health insurance coverage for cessation medications (one of the effective actions) is important for their use and effectiveness. Although there have been accelerating calls from advocates for this coverage and a parallel increase in health plans and government programs providing such coverage, the evidence base is both recent and limited. Three major studies now suggest that coverage or cost sharing may only be effective when _combined with extraordinary efforts to ensure that smokers are aware of the benefit and can access it easily. However, it is unclear whether many payors are willing to do that. Chronic disease management programs should definitely be focusing on whatever they can do to encourage smoking cessation. There is good evidence that repeated advice and support (and pharmacotherapy) from a variety of healthcare professionals is effective, especially when it is combined with the other care that patients receive. Since few other patient behaviors contribute as much to the causes and complications of most chronic diseases, great emphasis should be placed on changing this one.
Download InfoIf you experience problems downloading a file, check if you have the proper application to view it first. In case of further problems read the IDEAS help page. Note that these files are not on the IDEAS site. Please be patient as the files may be large.
As the access to this document is restricted, you may want to look for a different version under "Related research" (further below) or search for a different version of it.
Bibliographic InfoArticle provided by Springer Healthcare | Adis in its journal Disease Management & Health Outcomes.
Volume (Year): 13 (2005)
Issue (Month): 3 ()
Contact details of provider:
Web page: http://diseasemanagement.adisonline.com/
Bupropion; Nortriptyline; Smoking-cessation-therapies;
Find related papers by JEL classification:
- C - Mathematical and Quantitative Methods
- D - Microeconomics
- I - Health, Education, and Welfare
- Z - Other Special Topics
- I1 - Health, Education, and Welfare - - Health
- I19 - Health, Education, and Welfare - - Health - - - Other
- I18 - Health, Education, and Welfare - - Health - - - Government Policy; Regulation; Public Health
- I11 - Health, Education, and Welfare - - Health - - - Analysis of Health Care Markets
You can help add them by filling out this form.
reading list or among the top items on IDEAS.Access and download statistics
For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: (Dave Dustin).
If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.
If references are entirely missing, you can add them using this form.
If the full references list an item that is present in RePEc, but the system did not link to it, you can help with this form.
If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your profile, as there may be some citations waiting for confirmation.
Please note that corrections may take a couple of weeks to filter through the various RePEc services.